Alendronate, osteoporosis, and atherosclerosis

Archives of Internal Medicine

Volumn 168, Issue 21, 2008, Pages 2386-2387

  Strandberg, Timo E ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 56749150684     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.21.2386-c     Document Type: Letter

References (5)

1. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826-831.
2. Cauley JA, Ensrud KE. Considering competing risks . . . not all black and white. Arch Intern Med. 2008;168(8):793-795.
3. McCarthy I. The physiology of bone blood flow: a review. J Bone Joint Surg Am. 2006;88(suppl 3):4-9.
4. Varma R, Aronow WS, Basis Y, et al. Relation of bone mineral density to frequency of coronary heart disease. Am J Cardiol. 2008;101(8):1103-1104.
5. Lip GYH, Tse H-F. Management of atrial fibrillation. Lancet. 2007;370(9587):604-618.